Safety Assessment of Caprylhydroxamic Acid as Used in Cosmetics
Monice M Fiume1, Wilma F Bergfeld2, Donald V Belsito2
1Cosmetic Ingredient Review Senior Director.
International Journal of Toxicology
|July 17, 2025
Summary
The Expert Panel for Cosmetic Ingredient Safety found Caprylhydroxamic Acid safe for cosmetic use. They advised caution with damaged skin due to potential sensitization, recommending use that limits penetration.
Area of Science:
- Cosmetic Science
- Dermatology
- Toxicology
Background:
- Caprylhydroxamic Acid is utilized in cosmetics as a chelating agent.
- Concerns were raised regarding potential skin sensitization.
- Previous assessments indicated a need for further safety evaluation.
Purpose of the Study:
- To assess the safety of Caprylhydroxamic Acid in cosmetic products.
- To determine safe usage concentrations and conditions.
- To evaluate the risk of skin sensitization.
Main Methods:
- A comprehensive review of existing data was conducted.
- A quantitative risk assessment (QRA) was performed.
- A weight-of-evidence no-expected-sensitization-induction-level (WoE NESIL) was established.
Main Results:
- Sensitization reactions were observed, particularly on damaged skin.
- A WoE NESIL of 1056 μg/cm² was determined.
- The risk assessment indicated safety under specific conditions.
Conclusions:
- Caprylhydroxamic Acid is considered safe for cosmetic applications at current concentrations.
- Use on damaged skin should be avoided to minimize sensitization risk.
- Further research may be needed for specific application scenarios.
Keywords:
Caprylhydroxamic AcidCosmetic Ingredient ReviewCosmeticsExpert Panel for Cosmetic Ingredient SafetySafetyMore Related Videos
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...